Cardiff Oncology, Inc.
CRDFHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cardiff Oncology, Inc. focuses on Biotechnology services and products. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. The $65.3M market capitalization puts CRDF squarely in micro-cap range for its industry. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Market Cap
$65.3M
Beta
1.44
P/E (TTM)
—
P/E (Fwd)
-1.03
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.81
ROE
-84.8%
ROA
-44.3%
Cash
$46.1M
Total Debt
$646,000
Free CF
-$20.0M
52W Change
-77.8%
Annual Financials
Cash vs Debt
Where CRDF stands vs its 150-day and 200-day moving averages
As of the July 7, 2026 close, CRDF finished 32.29% below its 150-day moving average ($1.92) and 34.34% below its 200-day moving average ($1.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRDF overbought or oversold?
At the July 7, 2026 close, CRDF's RSI(14) was 33.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $46.1M in cash comfortably exceeding the $646K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$20.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -84.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $386K (2022) to $593K (2025), reflecting a 54% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cardiff Oncology, Inc. and its sector.